Advaxis To Seek New Life In Merger With Ayala
The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.
You may also be interested in...
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
The companies’ respective gamma-secretase inhibitors provided positive data for desmoid tumors at the ESMO congress but SpringWork’s nirogacestat impressed the most.
SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.